Resting energy tests in people with normal digestion vs. intestinal failure
Official title: Comparison of Resting Energy Expenditure According to Gastrointestinal Functional Status
Run by Institute of Oncology Ljubljana · NCT07714499 · Data updated 2026-11-12
This study tests resting energy expenditure in adults with and without intestinal failure to help tailor nutrition needs.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 92 (estimated) |
| Sponsor | Institute of Oncology Ljubljana Academic / other |
| Locations | 1 site (Ljubljana) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | October 1, 2026 |
| Study ends | October 1, 2026 |
| Registry record updated | July 20, 2026 |
| Trial ID | NCT07714499 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 with either normal GI function or clinically confirmed intestinal failure who are stable and able to attend a single study visit.
✕Probably not a fit
Patients with unstable conditions or comorbidities that affect energy expenditure may not benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, comparative study compares resting energy expenditure in adults with normal gastrointestinal function to those with intestinal failure. Participants undergo indirect calorimetry after fasting, body composition assessment by DEXA and bioelectrical impedance, and blood testing for inflammation in a single visit at the Institute of Oncology Ljubljana. The study uses two non-randomized groups: healthy controls and adults with intestinal failure, including short bowel syndrome and other causes. The goal is to understand how GI status and body composition influence energy requirements to improve nutritional support.
Why it matters
Potential benefit: If successful, results could improve individualized nutritional planning for people with intestinal failure.
How similar studies have gone: Prior studies in related populations have shown meaningful differences in energy expenditure with GI disease, supporting the relevance of this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Group A - Healthy Controls: * Age 18 to 65 years * No diagnosed chronic diseases * No hospitalization within the previous 30 days * No acute illness within the previous 14 days Group B - Participants With Intestinal Failure: * Age 18 to 65 years * Diagnostically confirmed intestinal failure * Stable clinical condition Exclusion Criteria: * Uncontrolled hyperthyroidism or hypothyroidism * Diabetes mellitus with poor glycemic control * Adrenal gland disease * Active inflammatory bowel disease, including Crohn's disease or ulcerative colitis * Celiac disease * Chronic pancreatitis * Active gastric or esophageal disease * Irritable bowel syndrome with significant symptoms * History of major abdominal surgery that permanently affects gastrointestinal function, except in participants with intestinal failure when this forms part of the condition under study * Heart failure * Active ischemic heart disease or recent myocardial infarction * Chronic obstructive pulmonary disease * Respiratory failure or need for long-term oxygen therapy * Progressive neurodegenerative disease * Dementia impairing the ability to participate * Severe stroke with significant functional impairment * Active tuberculosis * HIV/AIDS with clinically significant immunosuppression * Active systemic autoimmune disease * Active malignant disease * Advanced liver cirrhosis * Chronic kidney disease * Treatment with hemodialysis or peritoneal dialysis * Pregnancy or breastfeeding
Where it's running
-
Institute of Oncology Ljubljana
Ljubljana, Slovenia Recruiting
Study contacts
- Study coordinator: Klemen Schara, MSc
- Email: kschara@onko-i.si
- Phone: +38631630065
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FT1 for adults with short bowel syndrome: a safe, quick-study test
This trial tests FT1 vs placebo in adults with short bowel syndrome to see if FT1 is safe and helps with their condition.
-
Anabolic response to IV amino acids in people with chronic intestinal failure
This will test whether giving IV amino acids helps people with chronic intestinal failure on home parenteral nutrition build and maintain body protein and better match their individual protein needs.
-
AI-guided IV nutrition for newborns in the NICU
This project will try an AI tool that suggests IV nutrition (TPN) for newborns in the NICU who cannot feed by mouth to see if it helps clinicians order the right formula more quickly and accurately.
-
Glepaglutide for adults with short bowel syndrome and intestinal failure
This trial tests whether glepaglutide 10 mg given twice weekly can reduce the need for parenteral support in adults with short bowel syndrome and intestinal failure.
-
Crofelemer for adults with short bowel syndrome and intestinal failure without a colon
This trial will test whether taking crofelemer three times a day helps adults with short bowel syndrome and intestinal failure who lack a colon and need parenteral support.
-
Creating a quick quality-of-life questionnaire for people with short bowel syndrome
This project will try a shorter, easier quality-of-life questionnaire for adults with short bowel syndrome and compare it with the existing SBS QoL tool.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.